tag:blogger.com,1999:blog-12602489.post7457939545062448600..comments2024-03-24T15:07:18.773+01:00Comments on The Stuttering Brain: Pagoclone outlicensing negotiationsTom Weidighttp://www.blogger.com/profile/02084153394215001999noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-12602489.post-63802079788126267942007-12-04T19:45:00.000+01:002007-12-04T19:45:00.000+01:00P.S. The Blogger software apparently doesn't make...P.S. The Blogger software apparently doesn't make it easy to click on long links. Here's the link again, cut up in pieces to be visible:<BR/><BR/>http://findarticles.com/p/<BR/>articles/mi_m0EIN/is_2006_Sept_26/<BR/>ai_n16838040Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-12602489.post-80232779963989785472007-12-04T19:38:00.000+01:002007-12-04T19:38:00.000+01:00I was excited to talk with the Indevus representat...I was excited to talk with the Indevus representative yesterday and to discover that they have not abandoned pagaclone, which is what we have all been fearing in recent months based on the relative lack of activity or information after the September 2006 announcement of the Phase III study. (At that time they announced that they "will initiate a Phase III trial in the first half of 2007" - http://findarticles.com/p/articles/mi_m0EIN/is_2006_Sept_26/ai_n16838040 )<BR/><BR/>Nonetheless, I agree entirely with Tom's comment "It is important to watch their actions on the outlicensing as opposed to their words. We cannot judge the state of such negotiations and need to wait until a public announcement by both companies." We all know of cases where deals that were confidently described as all-but-certain fell through at the last minute. <BR/><BR/>At this point I think I'm more optimistic than Tom is, but I agree with his caution.Anonymousnoreply@blogger.com